CONTROLLING COSTS AND IMPROVING ACCESS, EQUITY, AND QUALITY ARE CRITICAL GOALS FOR AN EFFECTIVE AND EFFICIENT HEALTH CARE DELIVERY SYSTEM. CONSOLIDATION HAS DRAMATICALLY ALTERED HEALTH CARE MARKETS THROUGHOUT THE COUNTRY IN WAYS THAT LIMIT THEIR ABILITY TO ACHIEVE THESE GOALS. SPECIFICALLY, RESEARCH HAS REPEATEDLY SHOWN THAT CONSOLIDATION LEADS TO HIGHER PRICES AND REDUCED ACCESS TO ESSENTIAL SERVICES.\(^1\)\(^2\)

LIKE MANY OTHER PARTS OF THE COUNTRY, OREGON HAS EXPERIENCED SIGNIFICANT CONSOLIDATION IN THE HEALTH CARE INDUSTRY. SINCE 2020, CONCERNS HAVE INTENSIFIED THAT PROVIDER FINANCIAL STRUGGLES EXACERBATED BY THE COVID-19 PANDEMIC WOULD DRIVE FURTHER CONSOLIDATION.\(^3\) A RECENT REPORT FROM THE OREGON HEALTH AUTHORITY (OHA) FOUND THAT HEALTH CARE COSTS PER PERSON IN OREGON GREW BY 49% FROM 2013 TO 2019, FASTER THAN THE NATIONAL AVERAGE AND FASTER THAN INCOME AND INFLATION.\(^4\) THE SERVICE CATEGORIES THAT EXPERIENCED THE FASTEST INCREASES WERE OUTPATIENT SERVICES, PROFESSIONAL SERVICES, PHARMACY, AND EMERGENCY SERVICES.\(^4\)

UNSurprisingly, these rising costs have resulted in Oregonians spending more of their income on health care, using savings to pay medical bills, incurring debt or medical bankruptcy, delaying medical care, or going without care altogether.\(^5\) Although rising costs can be attributed to a variety of factors, oversight of future consolidation is critical to any effort to protect the people of Oregon from continued cost increases that jeopardize their health and financial stability.

In light of these troubling statistics, the Oregon legislature passed a law in 2021 creating a health care market oversight program and endowed the OHA with the authority to address the unchecked rise in consolidation and the downstream impacts on cost, access, equity, and quality. Although state and federal antitrust enforcement continues to be a crucial tool to combat consolidation in health care markets, the extensive time and resources needed to litigate such cases often limit its use to particularly large and egregious cases. State health care market oversight programs, like Oregon’s, can serve as important complements to antitrust enforcement as these programs can review transactions of various sizes, examine the cumulative effects of small transactions on markets, and evaluate transactions across a much wider array of factors beyond just antitrust implications.
When establishing the Health Care Market Oversight Program (HCMO), the Oregon legislature looked to Massachusetts’s pioneering Health Policy Commission (HPC) and went a step further by granting OHA the authority to block transactions outright or impose conditions to mitigate the potential for adverse effects. OHA receives notice of a wide range of health care entity transactions and engages in pretransaction reviews that include an in-depth analysis of the potential effects of transactions on cost, competition, access, equity, and quality and encompasses a broad scope of transactions involving a wide range of health care entities that reach the established financial threshold.

OHA’s review process uses a two-phase framework, which consists of a preliminary review and, if warranted, a comprehensive review. Upon receipt of a notice of a proposed transaction, OHA has 30 days to complete its preliminary review. At this phase of the review process, OHA examines readily available data to make an initial determination of whether the transaction is critical to an entity’s solvency and the potential impacts of the proposed transaction on cost, access, equity, and quality of health services. After the preliminary review, OHA may approve or conditionally approve the transaction; however, if there are indications during the preliminary review that the transaction may lead to significant adverse effects on cost, access, equity, or quality, OHA may then engage in a comprehensive review. The comprehensive review, which must be completed within 180 days of the initial notice, takes a deeper dive into the factors assessed during the preliminary review. It will likely examine additional data beyond what was used in the first review and may, at OHA’s discretion, include input from the community through a Community Review Board.

OHA is also charged with post-transaction monitoring and oversight and is required to conduct post-transaction reviews one, two, and five years after they occur. Furthermore, OHA has demonstrated its dedication to transparency by making information on potential transactions readily available to the public on its website, including notices, public comments, review reports, and final decisions. Finally, OHA must complete a statewide study of the impact of health care consolidation every four years to monitor Oregon’s changing health care landscape and address concerning consolidation trends.

Although the HCMO program is new and to date has completed only a few reviews, Oregon has established one of the strongest merger oversight programs in the country. While it is too soon to draw any definitive conclusions about its effectiveness and impact, the early implementation of the law provides insight into the benefits and challenges of implementing a health care market oversight program. The choices made in implementing the HCMO program offer multiple valuable considerations for other states seeking to address harmful consolidation in health care markets. To implement an effective market oversight program:

1. State policymakers need a detailed understanding of the drivers of health care costs in the state.
2. State legislators should aim to give a health care market oversight program as much authority as possible to allow flexibility.
3. States should strike a balance when deciding the breadth of review to use state resources effectively.

4. States should strive for a high-level of transparency and public participation, as both are critical to effectively review transactions and minimize the risk of regulatory failure.

5. Any imposed conditions should be enforceable and targeted.

This report provides an overview of the HCMO program, including a discussion of the transactions that are subject to review, the review process, and post-transaction monitoring and compliance. It also presents the work of the program to date. Finally, the report discusses the current legal challenge to the program and offers broad considerations for other states considering implementing or strengthening policies to oversee and address health care consolidation.
NOTES


ABOUT THE AUTHORS

Robin L. Davison, JD, MPH, is a senior health policy researcher for The Source on Healthcare Price and Competition and a research fellow for Dementia Care Aware, a California statewide initiative to improve screening and support for elderly Medicaid patients. Prior to joining the Consortium, she worked as a public health advisor for the Centers for Disease Control and Prevention and project lead for medical-legal partnerships research and implementation focused on underserved communities and people living with HIV. She holds a JD from Cardozo School of Law, an MPH from Columbia University, and a BA from Brandeis University.

Katherine L. Gudiksen, MS, PhD, is a senior health policy researcher for the Source on Healthcare Price and Competition. She studies the effects of consolidation and options that state policymakers have to address it, including laws to restrict specific contracting practices, state public option programs, and ways to limit excessive provider rates. She is a graduate of the UCSF/UC Hastings Master of Science in Health Policy and Law program, where she studied policy solutions to promote competition in the pharmaceutical industry. Prior to her work in health policy, she earned a PhD in chemistry from Harvard University and co-founded a cancer diagnostics company.

Alexandra D. Montague, JD, is a health policy researcher at the Source on Healthcare Price and Competition. She is a graduate of UC Hastings College of the Law, where she was the executive editor of articles for the Hastings Constitutional Law Quarterly and graduated with a concentration in health law.

Jaime S. King, JD, PhD, is the John and Marylyn Mayo Chair in Health Law and Professor of Law at the University of Auckland, Faculty of Law; senior affiliate scholar of the UCSF/UC Hastings, Consortium on Law, Science, and Health Policy; and executive editor of the Source on Healthcare Price and Competition. Professor King’s research analyzes the role of legal, economic, political, societal, and market forces in shaping domestic health care systems. Her U.S.-based work specifically focuses on the use of legal and policy initiatives to counteract concentration in health care and improve access to high-quality, affordable health care. She holds a JD from Emory University School of Law and a PhD in health policy from Harvard University.
About the Milbank Memorial Fund

The Milbank Memorial Fund is an endowed operating foundation that works to improve the health of populations and health equity by collaborating with leaders and decision makers and connecting them with experience and sound evidence. Founded in 1905, the Fund engages in nonpartisan analysis, collaboration, and communication on significant issues in health policy. It does this work by publishing high-quality, evidence-based reports, books, and The Milbank Quarterly, a peer-reviewed journal of population health and health policy; convening state health policy decision makers on issues they identify as important to population health; and building communities of health policymakers to enhance their effectiveness.

The Milbank Memorial Fund is an endowed operating foundation that engages in nonpartisan analysis, study, research, and communication on significant issues in health policy. In the Fund’s own publications, in reports, films, or books it publishes with other organizations, and in articles it commissions for publication by other organizations, the Fund endeavors to maintain the highest standards for accuracy and fairness. Statements by individual authors, however, do not necessarily reflect opinions or factual determinations of the Fund.

© 2023 Milbank Memorial Fund. All rights reserved. This publication may be redistributed digitally for noncommercial purposes only as long as it remains wholly intact, including this copyright notice and disclaimer.

Milbank Memorial Fund
645 Madison Avenue
New York, NY 10022
www.milbank.org